New insights into tetrahydrobiopterin pharmacodynamics from Pahenu1/2, a mouse model for compound heterozygous tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency

Biochemical Pharmacology

Volumn 80, Issue 10, 2010, Pages 1563-1571

  Lagler, Florian B ^a   Gersting, Søren W ^b   Zsifkovits, Clemens ^a   Steinbacher, Alice ^b   Eichinger, Anna ^b   Danecka, Marta K ^b   Staudigl, Michael ^b   Fingerhut, Ralph ^c,d   Glossmann, Hartmut ^a   Muntau, Ania C ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Labor Becker   (Germany)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Compound heterozygous; Mouse model; Pharmacodynamics; Phenylketonuria; Tetrahydrobiopterin

Indexed keywords

CARBON 13; PHENYLALANINE; PHENYLALANINE 4 MONOOXYGENASE; TETRAHYDROBIOPTERIN; BIOPTERIN; SAPROPTERIN; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DISEASE SEVERITY; DRUG CLEARANCE; DRUG EFFECT; GENOTYPE; HETEROZYGOSITY; MOUSE; NONHUMAN; PHARMACODYNAMICS; PHENYLKETONURIA; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; BREATH ANALYSIS; DEFICIENCY; DISEASE MODEL; DOSE RESPONSE; ENZYMOLOGY; GENETICS; HETEROZYGOTE; MUTANT MOUSE STRAIN; MUTATION; PHENYLKETONURIAS; TREATMENT OUTCOME;

ANIMALS; BIOPTERIN; BREATH TESTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HETEROZYGOTE; MICE; MICE, MUTANT STRAINS; MUTATION; PHENYLALANINE; PHENYLALANINE HYDROXYLASE; PHENYLKETONURIAS; TREATMENT OUTCOME; TYROSINE;

EID: 77957018961     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.07.042     Document Type: Article

References (39)

1. Shiman R., Gray D.W., Hill M.A. Regulation of rat liver phenylalanine hydroxylase. I. Kinetic properties of the enzymes iron and enzyme reduction site. J Biol Chem 1994, 269:24637-24646.
2. Shiman R., Xia T., Hill M.A., Gray D.W. Regulation of rat liver phenylalanine hydroxylase. II. Substrate binding and the role of activation in the control of enzymatic activity. J Biol Chem 1994, 269:24647-24656.
3. Xia T., Gray D.W., Shiman R. Regulation of rat liver phenylalanine hydroxylase. III. Control of catalysis by (6R)-tetrahydrobiopterin and phenylalanine. J Biol Chem 1994, 269:24657-24665.
4. Gersting S.W., Kemter K.F., Staudigl M., Messing D.D., Danecka M.K., Lagler F.B., et al. Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability. Am J Hum Genet 2008, 83:5-17.
5. Bonafé L., Blau N., Burlina A.P., Romstad A., Güttler F., Burlina A.B. Treatable neurotransmitter deficiency in mild phenylketonuria. Neurology 2001, 57:908-911.
6. Weglage J., Pietsch M., Feldmann R., Koch H.G., Zschocke J., Hoffmann G., et al. Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia. Pediatr Res 2001, 49:532-536.
7. Kure S., Hou D.C., Ohura T., Iwamoto H., Suzuki S., Sugiyama N., et al. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J Pediatr 1999, 135:375-378.
8. Muntau A.C., Röschinger W., Habich M., Demmelmair H., Hoffmann B., Sommerhoff C.P., et al. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N Engl J Med 2002, 347:2122-2132.
9. Steinfeld R., Kohlschütter A., Zschocke J., Lindner M., Ullrich K., Lukacs Z. Tetrahydrobiopterin monotherapy for phenylketonuria patients with common mild mutations. Eur J Pediatr 2002, 161:403-405.
10. Trefz F.K., Burton B.K., Longo N., Casanova M.M., Gruskin D.J., Dorenbaum A., et al. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr 2009, 154:700-707.
11. Burton B.K., Grange D.K., Milanowski A., Vockley G., Feillet F., Crombez E.A., et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J Inherit Metab Dis 2007, 30:700-707.
12. Levy H.L., Milanowski A., Chakrapani A., Cleary M., Lee P., Trefz F.K., et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet 2007, 370:504-510.
13. Lee P., Treacy E.P., Crombez E., Wasserstein M., Waber L., Wolff J., et al. Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Am J Med Genet A 2008, 146A:2851-2859.
14. Erlandsen H., Pey A.L., Gámez A., Pérez B., Desviat L.R., Aguado C., et al. Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc Natl Acad Sci USA 2004, 101:16903-16908.
15. Pey A.L., Pérez B., Desviat L.R., Martínez M.A., Aguado C., Erlandsen H., et al. Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations. Hum Mutat 2004, 24:388-399.
16. Gersting S.W., Lagler F.B., Eichinger A., Kemter K.F., Danecka M.K., Messing D.D., et al. Pahenu1 is a mouse model for tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency and promotes analysis of the pharmacological chaperone mechanism in vivo. Hum Mol Genet 2010, 19:2039-2049.
17. McDonald J.D., Bode V.C., Dove W.F., Shedlovsky A. The use of N-ethyl-N-nitrosourea to produce mouse models for human phenylketonuria and hyperphenylalaninemia. Prog Clin Biol Res 1990, 340C:407-413.
18. Shedlovsky A., McDonald J.D., Symula D., Dove W.F. Mouse models of human phenylketonuria. Genetics 1993, 134:1205-1210.
19. McDonald J.D., Charlton C.K. Characterization of mutations at the mouse phenylalanine hydroxylase locus. Genomics 1997, 39:402-405.
20. Sarkissian C.N., Boulais D.M., McDonald J.D., Scriver C.R. A heteroallelic mutant mouse model: a new orthologue for human hyperphenylalaninemia. Mol Genet Metab 2000, 69:188-194.
21. Lambruschini N., Pérez-Dueñas B., Vilaseca M.A., Mas A., Artuch R., Gassió R., et al. Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin monotherapy. Mol Genet Metab 2005, 86(Suppl. 1):S54-60.
22. Bélanger-Quintana A., García M.J., Castro M., Desviat L.R., Pérez B., Mejía B., et al. Spanish BH4-responsive phenylalanine hydroxylase-deficient patients: evolution of seven patients on long-term treatment with tetrahydrobiopterin. Mol Genet Metab 2005, 86(Suppl. 1):S61-S66.
23. Zurflüh M.R., Zschocke J., Lindner M., Feillet F., Chery C., Burlina A., et al. Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Hum Mutat 2008, 29:167-175.
24. Nielsen J.B., Nielsen K.E., Güttler F. Tetrahydrobiopterin responsiveness after extended loading test of 12 Danish PKU patients with the Y414C mutation. J Inherit Metab Dis 2010, 33:9-16.
25. Fiege B., Bonafé L., Ballhausen D., Baumgartner M., Thöny B., Meili D., et al. Extended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: a pilot study. Mol Genet Metab 2005, 86(Suppl. 1):S91-S95.
26. Karacić I., Meili D., Sarnavka V., Heintz C., Thöny B., Ramadza D.P., et al. Genotype-predicted tetrahydrobiopterin (BH4)-responsiveness and molecular genetics in Croatian patients with phenylalanine hydroxylase (PAH) deficiency. Mol Genet Metab 2009, 97:165-171.
27. Treacy E.P., Delente J.J., Elkas G., Carter K., Lambert M., Waters P.J., et al. Analysis of phenylalanine hydroxylase genotypes and hyperphenylalaninemia phenotypes using l-[1-13C]phenylalanine oxidation rates in vivo: a pilot study. Pediatr Res 1997, 42:430-435.
28. 2 in human bicarbonate studies: a critical review with original data. Clin Sci (Lond) 1996, 91:665-677.
29. Zurflüh M.R., Giovannini M., Fiori L., Fiege B., Gokdemir Y., Baykal T., et al. Screening for tetrahydrobiopterin deficiencies using dried blood spots on filter paper. Mol Genet Metab 2005, 86(Suppl. 1):S96-103.
30. Curtius H.C., Blau N., Kuster T.P. Techniques in diagnostic human biochemical genetics 1991, 377-396. Wiley-Liss, New York. F.A. Hommes (Ed.).
31. Koch H.J., Uyanik G., Raschka C., Schweizer J. The bi-exponential pharmacokinetic equation is suited to characterize lactate and ammonia concentration versus time data of the ischemic forearm exercise test. Neurol Rehabil 2002, 8:235-238.
32. Martínez A., Knappskog P.M., Olafsdottir S., Døskeland A.P., Eiken H.G., Svebak R.M., et al. Expression of recombinant human phenylalanine hydroxylase as fusion protein in Escherichia coli circumvents proteolytic degradation by host cell proteases. Isolation and characterization of the wild-type enzyme. Biochem J 1995, 306(Pt 2):589-597.
33. Miranda F.F., Kolberg M., Andersson K.K., Geraldes C.F., Martínez A. The active site residue tyrosine 325 influences iron binding and coupling efficiency in human phenylalanine hydroxylase. J Inorg Biochem 2005, 99:1320-1328.
34. Phillips R.S., Kaufman S. Ligand effects on the phosphorylation state of hepatic phenylalanine hydroxylase. J Biol Chem 1984, 259:2474-2479.
35. Knappskog P.M., Flatmark T., Aarden J.M., Haavik J., Martínez A. Structure/function relationships in human phenylalanine hydroxylase. Effect of terminal deletions on the oligomerization, activation and cooperativity of substrate binding to the enzyme. Eur J Biochem 1996, 242:813-821.
36. Leandro P., Rivera I., Lechner M.C., de Almeida I.T., Konecki D. The V388M mutation results in a kinetic variant form of phenylalanine hydroxylase. Mol Genet Metab 2000, 69:204-212.
37. Sanford M., Keating G.M. Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia. Drugs 2009, 69:461-476.
38. Fan J.Q. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity. Biol Chem 2008, 389:1-11.
39. Zurflüh M.R., Fiori L., Fiege B., Ozen I., Demirkol M., Gärtner K.H., et al. Pharmacokinetics of orally administered tetrahydrobiopterin in patients with phenylalanine hydroxylase deficiency. J Inherit Metab Dis 2006, 29:725-731.